Pittsburgh Business Times- UPMC Enterprises, the medical technology investment arm of UPMC, has purchased interest in RxAnte, a company that uses analytics to predict how patients will adhere to the medications they’re prescribed.
RxAnte will continue to operate as an independent company, and the investment from UPMC Enterprises will allow it to expand its offerings for Medicare, Medicaid and commercial populations, and to extend its predictive models and workflow tools to high-cost specialty drugs.
Recent Posts
A Year in Review: A comprehensive look at UPMC Enterprises 2020
Over the last year, UPMC Enterprises, our portfolio companies, and select partners have all supported UPMC’s mission of Life Changing Medicine. In the booklet below, we have compiled highlights from a truly unique year and recognize the team members and projects that have enabled our success.
Read More →
Writing a Fully Unit Testable Android App: The journey begins at the start of your project
Even as recently as API 30, the platform continues to evolve in this unfortunate direction, …
Read More →
Machine Learning and Structural Bias in Health Care
In November 2020, the Center for Connected Medicine (CCM) convened a group of experts in …
Read More →